AXTA

AI Memo

Axalta Coating

As of 2026-08-19/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-19 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

AkzoNobel transaction progression • 2026-11-17

Base target: $38 / p=50% prob

Biggest risk

Reported net income and diluted EPS declined year over year because of merger and acquisition costs. Performance Coatings and Industrial volumes were lower in North America, leaving AXTA exposed to weak end-market demand, unfavorable mix, and transaction execution risk.

Invalidation

Break below $31 or thesis failure.

What would change my mind?

Q2 showed strong operational conversion: record Adjusted EBITDA and Adjusted Diluted EPS, improved free cash flow, and the lowest reported net leverage in company history. Refinish growth and positive price/mix support the case for continued earnings improvement [#SEC-8K-2026-07-28].

Research note

Recommendation

—

Confidence

medium

As of

2026-08-19

Base target

$38

p=50%

Bull target

$43

p=25%

Bear target

$31

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 margin and cash-flow follow-through
Operational improvement and deleveraging
Q2 showed strong operational conversion: record Adjusted EBITDA and Adjusted Diluted EPS, improved free cash flow, and the lowest reported net leverage in company history.

BearKey bullets

AkzoNobel closing, integration, synergy realization, and leverage outcomes remain uncertain.
North American volume weakness and unfavorable mix could offset price, currency, and acquisition benefits.
Reported earnings remain affected by merger and acquisition costs, making underlying earnings conversion harder to assess.

WatchKey bullets

AkzoNobel transaction progression

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $38 (p=50%)

Target spread vs base: +12% / -20%

Scenario probabilities

Bull Target: $43 (p=25%)Base Target: $38 (p=50%)Bear Target: $31 (p=25%)

Commentary

Primary Q2 operating evidence is constructive, but reported net income and diluted EPS declined and forward growth visibility is only modest. Recent coverage is concentrated on earnings and the AkzoNobel transaction; analyst revisions, options positioning, short interest, employee data, social coverage, and a verified post-print market-reaction explanation are unavailable. This supports a monitoring stance rather than a high-conviction upgrade.

As of 2026-08-19 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 margin and cash-flow follow-through
Operational improvement and deleveraging

Scenarios

Bull Target (Scenario probability)

$43 / p=25% prob

Base Target (Scenario probability)

$38 / p=50% prob

Bear Target (Scenario probability)

$31 / p=25% prob

Analysis 2026-08-19 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.55

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-17
AkzoNobel transaction progression
The AkzoNobel combination remains the principal event path in the prior baseline. The August 5 filing is transaction-related, but the available excerpt does not establish closing timing; execution and integration remain material uncertainties [#8-K-2026-08-05].
Prob 55.00% • Move 10.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

Q2 margin and cash-flow follow-through
2026-09-30
Q2 delivered record Adjusted EBITDA of $305 million, record Adjusted Diluted EPS of $0.72, free cash flow of $107 million, and net leverage of 2.2x. Follow-through depends on sustaining price/mix and cost discipline while North American volumes remain soft [#SEC-8K-2026-07-28].
Prob 60% • Move 4% • Priced-in 60%

Long-term Catalysts

Months to a year

Operational improvement and deleveraging
2027-08-19
A longer-term rerating would require continued EBITDA conversion, free-cash-flow generation, and balance-sheet improvement after transaction-related costs, without a renewed deterioration in volumes or mix.
Prob 45% • Move 15% • Priced-in 45%

Risks

AkzoNobel closing, integration, synergy realization, and leverage outcomes remain uncertain.
North American volume weakness and unfavorable mix could offset price, currency, and acquisition benefits.
Reported earnings remain affected by merger and acquisition costs, making underlying earnings conversion harder to assess.
The available Form 4 records a 9,485-share CFO disposition for tax withholding/payment; it is not treated as evidence about operating performance [#SEC-FORM4-2026-08-18].
The packet lacks verified post-print analyst revisions, options data, social coverage, and a trusted explanation of the share-price reaction.

Peers

Symbol	Summary
SHW	Useful coatings benchmark for margin quality and end-market resilience, though larger and operationally cleaner than AXTA.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-19

Loading AI feed…

Symbol

Summary

SHW

Useful coatings benchmark for margin quality and end-market resilience, though larger and operationally cleaner than AXTA.